Matches in Nanopublications for { <http://rdf.disgenet.org/resource/nanopub/NP930036.RAFEaI7fUsN1ZFPfqvbrcwqPzXgDQFOI1Vj0L62aKhRUo130_assertion> ?p ?o ?g. }
Showing items 1 to 6 of
6
with 100 items per page.
- NP930036.RAFEaI7fUsN1ZFPfqvbrcwqPzXgDQFOI1Vj0L62aKhRUo130_assertion type Assertion NP930036.RAFEaI7fUsN1ZFPfqvbrcwqPzXgDQFOI1Vj0L62aKhRUo130_head.
- NP930036.RAFEaI7fUsN1ZFPfqvbrcwqPzXgDQFOI1Vj0L62aKhRUo130_assertion description "[Collectively, these data suggest that ABHD6 inhibitors may serve as therapeutics for obesity, nonalcoholic fatty liver disease, and type II diabetes.]. Sentence from MEDLINE/PubMed, a database of the U.S. National Library of Medicine." NP930036.RAFEaI7fUsN1ZFPfqvbrcwqPzXgDQFOI1Vj0L62aKhRUo130_provenance.
- NP930036.RAFEaI7fUsN1ZFPfqvbrcwqPzXgDQFOI1Vj0L62aKhRUo130_assertion evidence source_evidence_literature NP930036.RAFEaI7fUsN1ZFPfqvbrcwqPzXgDQFOI1Vj0L62aKhRUo130_provenance.
- NP930036.RAFEaI7fUsN1ZFPfqvbrcwqPzXgDQFOI1Vj0L62aKhRUo130_assertion SIO_000772 24095738 NP930036.RAFEaI7fUsN1ZFPfqvbrcwqPzXgDQFOI1Vj0L62aKhRUo130_provenance.
- NP930036.RAFEaI7fUsN1ZFPfqvbrcwqPzXgDQFOI1Vj0L62aKhRUo130_assertion wasDerivedFrom befree-20150227 NP930036.RAFEaI7fUsN1ZFPfqvbrcwqPzXgDQFOI1Vj0L62aKhRUo130_provenance.
- NP930036.RAFEaI7fUsN1ZFPfqvbrcwqPzXgDQFOI1Vj0L62aKhRUo130_assertion wasGeneratedBy ECO_0000203 NP930036.RAFEaI7fUsN1ZFPfqvbrcwqPzXgDQFOI1Vj0L62aKhRUo130_provenance.